BioNotebook: Xencor regains rights from Amgen; plus three other deals
This article was originally published in Scrip
Executive Summary
Xencor gains greater control in Amgen pact; Zogenix buys Brabant Pharma; CTI BioPharma buys worldwide rights to tosedostat; and Takeda licenses Mersana ADC.
You may also be interested in...
Xencor's Coming Share Issue To Help Fund Immuno-Oncology Pipeline
Monrovia, California-based Xencor Inc.'s latest funding exercise is a public share offering to raise some $110m after expenses to advance its immuno-oncology pipeline.
Novartis Deal Gives Xencor $150m Up Front, Up To $2.41bn In Milestone Fees
Monrovia, California-based Xencor Inc.'s latest collaboration, which is worth $150m up front and up to $2.41bn in milestone fees from Novartis AG, shows how the company is growing up as its research and development pipeline matures.
Second Cellectis CAR-T Therapy On Clinical Hold, Dosing Could Be Issue
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.
Need a specific report? 1000+ reports available
Buy Reports